MAM
Mastiii proposes 30-45% hike in ad rates following better reach
MUMBAI: Music and youth channel Mastiii claims to have retained its dominance in the music & youth arena for over two years. With a reported reach of 136 million and 30 GRP in the genre, Mastiii recently announced a 30 to 45 per cent hike in advertising rates.
Mastiii claims to commands a market share of 18 per cent. Tapping into originality, the channel is at the forefront of innovation as it has introduced several ‘firsts’ to the audiences – like Mastiii Specials. The channel’s holistic and innovative approach to music, in addition to the consistent growth in ratings makes it the ideal platform for advertisers.
In a move to capitalise on the channel’s growing popularity, attributed to leading shows like ‘Mastiii Doubles’ & ‘Love Aajkal’, the ad rate hike has been well accepted. Recent releases like See TaareMastiiiMein, a celebrity chat show that had fun-filled viewer engagements with the likes of Amitabh Bachchan, Shah Rukh Khan, Salman Khan and many more; as well as the weekend special Mastiii Movie review has guaranteed buzz among the existing audience.
SABGROUP Group CEO Manav Dhanda said, “Mastiii stands out across almost all possible age-groups in HSM urban, with a dominance in NCCS AB. We are also the largest youth audience aggregator in the music & youth genre across age cuts like 15+ and 22+. We have received positive response from advertisers.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
